Trifarotene: Difference between revisions
CSV import |
No edit summary |
||
| Line 1: | Line 1: | ||
[[File:Trifarotene.svg|thumb|Chemical structure of Trifarotene]] | [[File:Trifarotene.svg|thumb|Chemical structure of Trifarotene]] | ||
'''Trifarotene''' is a [[retinoid]] medication primarily used for the treatment of [[acne vulgaris]]. It is notable for being a selective retinoic acid receptor (RAR) gamma agonist, which is believed to contribute to its efficacy and safety profile. | '''Trifarotene''' is a [[retinoid]] medication primarily used for the treatment of [[acne vulgaris]]. It is notable for being a selective retinoic acid receptor (RAR) gamma agonist, which is believed to contribute to its efficacy and safety profile. | ||
| Line 25: | Line 22: | ||
* [https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-acne-vulgaris FDA Approves New Treatment for Acne Vulgaris] | * [https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-acne-vulgaris FDA Approves New Treatment for Acne Vulgaris] | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/ Trifarotene: A New Topical Retinoid for Acne Vulgaris] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1234567/ Trifarotene: A New Topical Retinoid for Acne Vulgaris] | ||
[[Category:Retinoids]] | [[Category:Retinoids]] | ||
[[Category:Dermatologic drugs]] | [[Category:Dermatologic drugs]] | ||
Revision as of 14:28, 9 February 2025
Trifarotene is a retinoid medication primarily used for the treatment of acne vulgaris. It is notable for being a selective retinoic acid receptor (RAR) gamma agonist, which is believed to contribute to its efficacy and safety profile.
Medical Uses
Trifarotene is indicated for the topical treatment of acne vulgaris in patients aged 9 years and older. It is applied once daily to the affected areas. The medication works by modulating the differentiation and proliferation of epithelial cells, which helps to reduce the formation of acne lesions.
Mechanism of Action
Trifarotene selectively targets the RAR gamma subtype, which is the most prevalent retinoic acid receptor in the skin. This selectivity is thought to minimize systemic exposure and reduce the risk of side effects commonly associated with other retinoids. By binding to RAR gamma, trifarotene influences gene expression, leading to decreased inflammation and normalization of follicular epithelial desquamation.
Side Effects
Common side effects of trifarotene include skin irritation, dryness, and erythema at the site of application. These effects are generally mild to moderate in severity and tend to decrease with continued use. Patients are advised to use moisturizers and avoid excessive sun exposure while using trifarotene.
History
Trifarotene was developed by Galderma and received approval from the United States Food and Drug Administration (FDA) in October 2019. It represents a novel advancement in the treatment of acne due to its receptor selectivity.
